A first-ever vaccine designed to deliver a one-two-three punch against the main causes of traveller’s diarrhea worldwide may result from new research published by a University of Guelph chemist.
Prof. Mario Monteiro says his novel three-in-one approach to developing a new vaccine could also save lives in developing countries, where it’s estimated that these three common pathogens kill more than 100,000 children under age five each year.
His research was recently published in the journal Vaccine.
The paper discusses Monteiro’s so-called conjugate vaccine that yokes together proteins from pathogenic E. coli with sugars from Shigella and Campylobacter jejuni. All three bugs are major causes of bacterial diarrhea globally.
In tests with mice, the vaccine provided immunity against all three pathogens.
No licensed vaccines exist against any of these pathogens. A sugar-based vaccine developed by Monteiro in 2009 against campylobacter alone is currently undergoing human trials but is still an estimated decade away from potential release.
He said this new three-in-one approach may ultimately overtake that earlier single-target vaccine, although any new vaccine may take decades to test and release. “We’re targeting three pathogens at the same time,” he said. “Instead of three shots, maybe you only need one.”
As with the earlier campylobacter vaccine, this new method has been patented by U of G and the United States Naval Medical Research Center, which funded the research.
Monteiro said further research is needed to determine the optimum amounts of protein and sugars in the vaccine and to make the vaccine more efficient.
The Latest on: Traveller’s diarrhea
via Google News
The Latest on: Traveller’s diarrhea
- 10 Travel Tips for Chronic Digestive Disorder | Health Plus on February 7, 2019 at 10:36 am
Tell your travel companions what you suffer from ... Make sure you drink water regularly through the flight and during your holiday. Similarly, if you have diarrhoea, you’ll need to replenish the flui... […]
- Preventing scours in calves on February 5, 2019 at 1:06 am
According to George Barrington, Washington State University, diarrhea results in the greatest economic loss ... "It helps to feed some distance away from water so cattle have to travel between feed an... […]
- Health Tip: Prevent Travelers' Diarrhea on January 10, 2019 at 4:10 am
(HealthDay News) -- A vacation or business trip to a developing country can lead to a nasty case of travelers' diarrhea -- if you're not careful. The U.S. National Institute of Diabetes and Digestive ... […]
- Going Abroad? Prevent Travelers' Diarrhea with These 5 Tips on December 23, 2018 at 11:36 pm
You’ve saved for months for the trip of your dreams. You hop off the plane and head to the first food spot you see to treat yourself to some exotic local cuisine. Later that evening, you start to feel ... […]
- FDA approves drug for treatment of travelers' diarrhea on November 22, 2018 at 1:02 am
(HealthDay)—The U.S. Food and Drug Administration on Friday announced it has approved Aemcolo (rifamycin), an antibacterial drug indicated for treating adult patients with travelers' diarrhea caused b... […]
- Cosmo Pharma receives US FDA approval for Aemcolo to treat travelers’ diarrhea on November 20, 2018 at 3:44 am
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Aemcolo (Rifamycin), containing 194mg of Rifamycin as delayed-rele... […]
- FDA nod for Cosmo's travelers' diarrhea med Aemcolo pressures Bausch Health, down 5% on November 19, 2018 at 8:26 am
Bausch Health Companies (BHC-5%) is down on below-average volume in apparent response to FDA approval of Cosmo Technologies' Aemcolo (rifamycin) for the treatment of travelers' diarrhea caused by noni... […]
- FDA Approves AEMCOLO™ (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade on November 19, 2018 at 5:21 am
SAN DIEGO, Nov. 19, 2018 /PRNewswire/ -- Aries Pharmaceuticals, Inc. (a Cosmo Pharmaceuticals N.V. Company) announced today that the U.S. Food and Drug Administration (FDA) has approved AEMCOLO™ (rifa... […]
- Cosmo’s diarrhoea drug approved, threatening Salix’ cash cow on November 18, 2018 at 10:29 pm
The US regulator cleared Aemcolo (rifamycin) for the treatment of adults with travellers’ diarrhoea caused by non-invasive strains of Escherichia coli not complicated by fever or blood in the stool, a ... […]
via Bing News